These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1132 related articles for article (PubMed ID: 23907365)
21. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis. García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914 [TBL] [Abstract][Full Text] [Related]
22. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162 [TBL] [Abstract][Full Text] [Related]
23. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002 [TBL] [Abstract][Full Text] [Related]
24. Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts. Fu P; Shen B; Zhao C; Tian G J Nucl Med; 2010 Nov; 51(11):1805-12. PubMed ID: 20956468 [TBL] [Abstract][Full Text] [Related]
25. MDM2 molecular imaging for the prediction of chemotherapeutic sensitivity in human breast cancer xenograft. Fu P; Sun L; Cao X; Li L; Zhao C Mol Imaging; 2014; 13():. PubMed ID: 25022573 [TBL] [Abstract][Full Text] [Related]
26. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway. Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458 [TBL] [Abstract][Full Text] [Related]
27. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118 [TBL] [Abstract][Full Text] [Related]
28. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662 [TBL] [Abstract][Full Text] [Related]
29. Dual-channel surface plasmon resonance monitoring of intracellular levels of the p53-MDM2 complex and caspase-3 induced by MDM2 antagonist Nutlin-3. Wu L; Hu Y; He Y; Xia Y; Lu H; Cao Z; Yi X; Wang J Analyst; 2019 Jul; 144(13):3959-3966. PubMed ID: 31134974 [TBL] [Abstract][Full Text] [Related]
31. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo. Riedel F; Götte K; Li M; Hörmann K; Grandis JR Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890 [TBL] [Abstract][Full Text] [Related]
32. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799 [TBL] [Abstract][Full Text] [Related]
33. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964 [TBL] [Abstract][Full Text] [Related]
34. Effects and mechanism of recombinant human erythropoietin on the growth of human breast cancer MDA-MB-231 cells in nude mice. Jin W; Lin Z; Zhang X; Kong L; Yang L Pathol Res Pract; 2015 Aug; 211(8):570-6. PubMed ID: 26008780 [TBL] [Abstract][Full Text] [Related]
35. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686 [TBL] [Abstract][Full Text] [Related]
36. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3. Yang P; Chen W; Li X; Eilers G; He Q; Liu L; Wu Y; Wu Y; Yu W; Fletcher JA; Ou WB Oncotarget; 2016 May; 7(22):32652-63. PubMed ID: 27129163 [TBL] [Abstract][Full Text] [Related]
37. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Lee YM; Lim JH; Chun YS; Moon HE; Lee MK; Huang LE; Park JW Carcinogenesis; 2009 Oct; 30(10):1768-75. PubMed ID: 19696166 [TBL] [Abstract][Full Text] [Related]
38. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768 [TBL] [Abstract][Full Text] [Related]
39. Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells. Ciccone V; Terzuoli E; Donnini S; Giachetti A; Morbidelli L; Ziche M J Exp Clin Cancer Res; 2018 Dec; 37(1):311. PubMed ID: 30541574 [TBL] [Abstract][Full Text] [Related]
40. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]